MEDICINOVA, INC.

Analyst Reco. MediciNova, Inc.

Equities

MNOV

US58468P2065

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-02 pm EDT			5-day change	1st Jan Change
1.38 ^USD	+6.98%		+1.85%	-8.00%

Mar. 27	MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan	CI
Mar. 12	Medicinova Announces New Data and Results of Mn-166 in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MediciNova Says Alcohol-Use Disorder Drug Reduced Rates of Heavy Drinking, Alcohol Craving in Mid-Stage Trial	22-04-08	MT
Maxim Group Adjusts MediciNova Price Target to $6 From $10, Maintains Buy Rating	22-02-02	MT
B. Riley Lowers MediciNova's Price Target to $6 from $11 After Revising Cost Capital Assumptions, Keeps Buy Rating	22-01-24	MT
MEDICINOVA : Maxim Starts MediciNova at Buy With $15 Price Target	21-03-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer